MTOR and neoplasm: When the tumor exceeds 4 cm and the symptoms become persistent, the therapeutic goal should be focused on preserving renal function to the maximum achievable degree, involving mesenchymal-sparing treatment such as partial nephrectomy, selective arterial embolization (SAE), ablation, and mTOR inhibitors in patients with TSC-associated AMLs [11].